These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24280140)

  • 41. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.
    Ferroni P; Basili S; Martini F; Cardarello CM; Ceci F; Di Franco M; Bertazzoni G; Gazzaniga PP; Alessandri C
    J Investig Med; 2003 Sep; 51(5):295-300. PubMed ID: 14577520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction.
    Schmidt R; Bültmann A; Ungerer M; Joghetaei N; Bülbül O; Thieme S; Chavakis T; Toole BP; Gawaz M; Schömig A; May AE
    Circulation; 2006 Feb; 113(6):834-41. PubMed ID: 16461815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
    Tyagi SC; Kumar SG; Haas SJ; Reddy HK; Voelker DJ; Hayden MR; Demmy TL; Schmaltz RA; Curtis JJ
    J Mol Cell Cardiol; 1996 Jul; 28(7):1415-28. PubMed ID: 8841929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extracellular matrix metalloproteinase inducer (EMMPRIN) is increased in human left ventricle after acute myocardial infarction.
    Nie R; Xie S; Du B; Liu X; Deng B; Wang J
    Arch Med Res; 2009 Oct; 40(7):605-11. PubMed ID: 20082877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive utility of the changes in matrix metalloproteinase-2 in the early phase for left ventricular reverse remodeling after an acute myocardial infarction.
    Morishita T; Uzui H; Mitsuke Y; Arakawa K; Amaya N; Kaseno K; Ishida K; Nakaya R; Lee JD; Tada H
    J Am Heart Assoc; 2015 Jan; 4(1):e001359. PubMed ID: 25616975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of surgery on the levels of matrix metalloproteinases in patients with inguinal hernia.
    Strohalmová S; Levová K; Kuběna AA; Krška Z; Hoskovec D; Zima T; Kalousová M
    Physiol Res; 2021 Aug; 70(4):627-634. PubMed ID: 34062071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
    Oszajca K; Szemraj M; Szemraj J; Jurowski P
    Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.
    Nakaya R; Uzui H; Shimizu H; Nakano A; Mitsuke Y; Yamazaki T; Ueda T; Lee JD
    Int J Cardiol; 2005 Oct; 105(1):67-73. PubMed ID: 16207547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents].
    Głowińska-Olszewska B; Urban M; Florys B
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):179-83. PubMed ID: 17020652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
    Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
    Vanhoutte D; Schellings M; Pinto Y; Heymans S
    Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study.
    Hansson J; Vasan RS; Ärnlöv J; Ingelsson E; Lind L; Larsson A; Michaëlsson K; Sundström J
    PLoS One; 2011 Jan; 6(1):e16185. PubMed ID: 21283828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin 18 and extracellular matrix metalloproteinase inducer cross-regulation: implications in acute myocardial infarction.
    Xie SL; Chen YY; Zhang HF; Deng BQ; Shu XR; Su ZZ; Lin YQ; Nie RQ; Wang JF
    Transl Res; 2015 Mar; 165(3):387-95. PubMed ID: 25267095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.
    Fukuda D; Shimada K; Tanaka A; Kusuyama T; Yamashita H; Ehara S; Nakamura Y; Kawarabayashi T; Iida H; Yoshiyama M; Yoshikawa J
    Am J Cardiol; 2006 Jan; 97(2):175-80. PubMed ID: 16442358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.